Comparison · NCT02994927-732d8dbd
Prednisone Group vs Avacopan Group: Number of Subjects Experiencing a Relapse After Previously Achieving BVAS=0 During the Study
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Prednisone Group vs Avacopan Group: Number of Subjects Experiencing a Relapse After Previously Achieving BVAS=0 During the Study. Trial comparisons, record NCT02994927-732d8dbd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02994927-732d8dbd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.21 | 0.154 | 0.28 | wilson | |
| Risk in group 2 | 0.101 | 0.0633 | 0.158 | wilson | |
| Risk difference, group 1 minus group 2 | 0.109 | 0.0288 | 0.189 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.08 | 1.19 | 3.61 | log | |
| Odds ratio, group 1 over group 2 | 2.36 | 1.24 | 4.5 | log | |
| Number needed to treat, for one more participant with the outcome on Prednisone Group than on Avacopan Group | 9.18 | 5.3 | 34.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Prednisone Group | Avacopan-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone. | 33 | 157 | OG000 |
| Group 2 | Avacopan Group | Avacopan plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo. | 16 | 158 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Experiencing a Relapse After Previously Achieving BVAS=0 During the Study
- Description
BVAS=Birmingham Vasculitis Activity Score;~A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after:~1. having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or~2. having achieved BVAS=0 at any time during the treatment period~The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health).
- Time frame
- From day 1 throughout the study period (day 421/week 60)
- Population
- Intended-to-Treat (ITT) Population: The ITT Population included all subjects who were randomized in the study and who received at least one dose of blinded study drug.
Source ClinicalTrials.gov
Trial
- Title
- A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
- NCT number
- NCT02994927
- Phases
- PHASE3
- Conditions
- ANCA-Associated Vasculitis
- Interventions
- Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine
- Lead sponsor
- Amgen
- Results first posted
- 2022-09-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02994927?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02994927-732d8dbd